Merck (MRK) announced that the U.S. FDA has granted priority review for two supplemental Biologics License Applications for Keytruda and Keytruda Qlex, each in combination with Padcev, for the treatment of patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy. The FDA set a Prescription Drug User Fee Act, or target action, date of April 7, 2026, marking the first concurrent review of both Keytruda and Keytruda Qlex for the same novel indication.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Trump Trade: Trump administration prepares new probe into pharma prices
- Trump admin prepares new probe into U.S. pharma prices, FT says
- Merck, Flare Therapeutics enter clinical trial collaboration, supply agreement
- Merck announces new long-term Keytruda data
- Evaxion Biotech price target raised to $11 from $6 at Lake Street